<?xml version="1.0" encoding="UTF-8"?>
<ref id="B39">
 <label>39.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Scully</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Cataland</surname>
    <given-names>SR</given-names>
   </name>
   <name>
    <surname>Peyvandi</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Coppo</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Knobl</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Kremer Hovinga</surname>
    <given-names>JA</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura.</article-title>
  <source>
   <italic>N Engl J Med.</italic>
  </source> (
  <year>2019</year>) 
  <volume>380</volume>:
  <fpage>335</fpage>â€“
  <lpage>46</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1806311</pub-id>
  <?supplied-pmid 30625070?>
  <pub-id pub-id-type="pmid">30625070</pub-id>
 </mixed-citation>
</ref>
